89Bio Inc (ETNB)

$14.84 0.00 (N/A)
Market Cap 2.20B
Revenue (ttm) 0.00
Net Income (ttm) -367.08M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.07
Volume 55,645,300
Avg Vol 6,452,184
Day's Range N/A - N/A
Shares Out 148.31M
Stochastic %K 77%
Beta 1.27
Analysts Sell
Price Target $31.64

Company Profile

89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. 89bio, Inc. was formerly known as The company was founded in 2018 and is based in San Francisco, California. As of October 29, 2...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 432 9270
Address:
655 Montgomery Street, Suite 1500, San Francisco, United States
BULLETSTOCK
BULLETSTOCK Nov. 14 at 11:25 AM
$ADTX Will be the next $ETNB will see $$$$$$$$$$$
0 · Reply
Orkay
Orkay Nov. 12 at 8:30 PM
$VKTX $MTSR $ETNB $AKRO bought out in past 3 months. Viking is far ahead of them and MASH assets. $15B min.
0 · Reply
DG20
DG20 Nov. 11 at 8:55 PM
$AKRO $ETNB $MDGL $VKTX Pemvidutide is the only GLP that does NOT treat diabetes. STOP SPAMMING the Viking board!!!
0 · Reply
PemvidutideTrader7B
PemvidutideTrader7B Nov. 11 at 8:51 PM
$ALT $VKTX $ETNB $AKRO $MDGL Let’s not forget weight loss!
0 · Reply
PemvidutideTrader7B
PemvidutideTrader7B Nov. 11 at 8:36 PM
$ALT $VKTX $ETNB $AKRO $MDGL Huge start out of the gates for Altimmune.
0 · Reply
Tdorsey1776
Tdorsey1776 Nov. 3 at 4:52 PM
$ETNB Acquisition settled....funds deposited and 89Bio CVRs sitting pretty. GLTA
0 · Reply
mrmarvyn
mrmarvyn Oct. 30 at 8:05 PM
$ETNB I guess that's it for ETNB. It's been a fun ride and hope in 5-10 years I receive a few presents. I'm going to remove them from my watch list.
0 · Reply
Gantz7
Gantz7 Oct. 30 at 3:38 PM
$ETNB And only just need to make 4 Billion in Net sales for one of the CVR products in a single year to get the 6 Dollar. It is staggered in three levels and runs to 2035. So gimme my share money back and I can reinvest it in something again. Today would be nice...
0 · Reply
Tdorsey1776
Tdorsey1776 Oct. 30 at 2:22 PM
$ETNB Keep stacking the CVRs!!! Good luck all
0 · Reply
Gantz7
Gantz7 Oct. 30 at 9:05 AM
$ETNB More CVRs to add to the pile...
0 · Reply
Latest News on ETNB
3 Investable Laggards In An Overbought Market

Oct 28, 2025, 5:13 PM EDT - 17 days ago

3 Investable Laggards In An Overbought Market

AVDL BMY MRUS MTSR NVS PAGP RNA

My Top 3 Pharma Stocks

Oct 20, 2025, 11:38 AM EDT - 25 days ago

My Top 3 Pharma Stocks

AKRO BMY LLY MRK NVO PFE SPY

89bio Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 89bio, Inc. - ETNB

Oct 6, 2025, 5:10 PM EDT - 5 weeks ago

89bio Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 89bio, Inc. - ETNB

3 Potential Biotech Acquisition Targets

Sep 19, 2025, 12:53 PM EDT - 2 months ago

3 Potential Biotech Acquisition Targets

AZN INCY MLYS SNDX TVTX

89BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 89bio, Inc. - ETNB

Sep 19, 2025, 12:24 PM EDT - 2 months ago

89BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 89bio, Inc. - ETNB

Roche To Acquire 89bio For $2.4 Billion In Liver And Cardiometabolic Push

Sep 18, 2025, 12:34 PM EDT - 2 months ago

Roche To Acquire 89bio For $2.4 Billion In Liver And Cardiometabolic Push

Roche to Buy 89bio for Up to $3.5 Billion

Sep 18, 2025, 1:29 AM EDT - 2 months ago

Roche to Buy 89bio for Up to $3.5 Billion

Roche to acquire liver drug developer 89bio for up to $3.5 billion

Sep 18, 2025, 1:18 AM EDT - 2 months ago

Roche to acquire liver drug developer 89bio for up to $3.5 billion

89bio, Inc. Announces Agreement to be Acquired by Roche

Sep 18, 2025, 1:02 AM EDT - 2 months ago

89bio, Inc. Announces Agreement to be Acquired by Roche

89bio, Inc. (ETNB) Presents At Cantor Global Healthcare Conference 2025 (Transcript)

Sep 9, 2025, 10:09 AM EDT - 2 months ago

89bio, Inc. (ETNB) Presents At Cantor Global Healthcare Conference 2025 (Transcript)

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 5, 2025, 4:05 PM EDT - 2 months ago

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

89bio, Inc. (ETNB) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 3, 2025, 3:05 PM EDT - 2 months ago

89bio, Inc. (ETNB) Presents At Citi's Biopharma Back To School Conference Transcript

89bio to Participate in Upcoming Investor Conferences

Aug 28, 2025, 4:05 PM EDT - 2 months ago

89bio to Participate in Upcoming Investor Conferences

89bio: Promising As Pegozafermin Nears Phase 3 Readout

Aug 11, 2025, 8:22 AM EDT - 3 months ago

89bio: Promising As Pegozafermin Nears Phase 3 Readout

89bio Reports Second Quarter 2025 Financial Results and Corporate Updates

Aug 7, 2025, 4:05 PM EDT - 3 months ago

89bio Reports Second Quarter 2025 Financial Results and Corporate Updates

89bio to Participate in Goldman Sachs 46th Annual Global Healthcare Conference

Jun 4, 2025, 4:05 PM EDT - 5 months ago

89bio to Participate in Goldman Sachs 46th Annual Global Healthcare Conference

89bio Reports First Quarter 2025 Financial Results and Corporate Updates

May 1, 2025, 4:05 PM EDT - 7 months ago

89bio Reports First Quarter 2025 Financial Results and Corporate Updates

89bio: A Buy With Strong Market Opportunity In MASH And SHTG

Apr 18, 2025, 4:46 AM EDT - 7 months ago

89bio: A Buy With Strong Market Opportunity In MASH And SHTG

89bio to Participate in the Leerink Partners Global Healthcare Conference

Mar 3, 2025, 4:05 PM EST - 9 months ago

89bio to Participate in the Leerink Partners Global Healthcare Conference

89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

Feb 27, 2025, 4:05 PM EST - 9 months ago

89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

89bio's Pegozafermin Is Now Gaining Momentum

Jan 30, 2025, 6:05 AM EST - 10 months ago

89bio's Pegozafermin Is Now Gaining Momentum

89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Jan 28, 2025, 10:31 PM EST - 10 months ago

89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Jan 27, 2025, 4:12 PM EST - 10 months ago

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

89bio: Advancement Of Pegozafermin For SHTG Is Another Path Forward

Jan 13, 2025, 6:08 PM EST - 10 months ago

89bio: Advancement Of Pegozafermin For SHTG Is Another Path Forward

89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024

Nov 15, 2024, 8:05 AM EST - 1 year ago

89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024

89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Nov 12, 2024, 11:58 PM EST - 1 year ago

89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants

89bio to Participate in the UBS Global Healthcare Conference

Nov 5, 2024, 4:05 PM EST - 1 year ago

89bio to Participate in the UBS Global Healthcare Conference

89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024

Oct 15, 2024, 8:30 AM EDT - 1 year ago

89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024

89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference

Sep 30, 2024, 4:05 PM EDT - 1 year ago

89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference

89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer

Sep 16, 2024, 4:05 PM EDT - 1 year ago

89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer

89bio: Bullish In Light Of Further MOA Being Established By Peer

Aug 7, 2024, 1:59 PM EDT - 1 year ago

89bio: Bullish In Light Of Further MOA Being Established By Peer

89bio Appoints Francis Sarena as Chief Operating Officer

Aug 7, 2024, 8:00 AM EDT - 1 year ago

89bio Appoints Francis Sarena as Chief Operating Officer

89bio Reports Second Quarter 2024 Financial Results and Corporate Updates

Aug 5, 2024, 4:05 PM EDT - 1 year ago

89bio Reports Second Quarter 2024 Financial Results and Corporate Updates

89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy

May 23, 2024, 6:32 AM EDT - 1 year ago

89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy

89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress

May 22, 2024, 4:05 PM EDT - 1 year ago

89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress

89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis

May 14, 2024, 8:00 AM EDT - 1 year ago

89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis

89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 4:05 PM EDT - 1 year ago

89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

89bio to Participate in the BofA Securities 2024 Health Care Conference

May 8, 2024, 4:05 PM EDT - 1 year ago

89bio to Participate in the BofA Securities 2024 Health Care Conference

89bio to Host Key Opinion Leader Webinar on Pegozafermin's Opportunity in Advanced MASH

May 2, 2024, 4:05 PM EDT - 1 year ago

89bio to Host Key Opinion Leader Webinar on Pegozafermin's Opportunity in Advanced MASH

89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors

Apr 17, 2024, 4:05 PM EDT - 1 year ago

89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors

89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis

Mar 27, 2024, 8:00 AM EDT - 1 year ago

89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis

89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis

Mar 12, 2024, 8:00 AM EDT - 1 year ago

89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis

89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mar 8, 2024, 4:05 PM EST - 1 year ago

89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

89bio to Participate in the Leerink Partners Global Biopharma Conference

Mar 5, 2024, 4:05 PM EST - 1 year ago

89bio to Participate in the Leerink Partners Global Biopharma Conference

89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Feb 29, 2024, 4:05 PM EST - 1 year ago

89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 6, 2024, 4:05 PM EST - 1 year ago

89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Dec 12, 2023, 7:30 AM EST - 2 years ago

89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Dec 7, 2023, 7:00 AM EST - 2 years ago

89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants

BULLETSTOCK
BULLETSTOCK Nov. 14 at 11:25 AM
$ADTX Will be the next $ETNB will see $$$$$$$$$$$
0 · Reply
Orkay
Orkay Nov. 12 at 8:30 PM
$VKTX $MTSR $ETNB $AKRO bought out in past 3 months. Viking is far ahead of them and MASH assets. $15B min.
0 · Reply
DG20
DG20 Nov. 11 at 8:55 PM
$AKRO $ETNB $MDGL $VKTX Pemvidutide is the only GLP that does NOT treat diabetes. STOP SPAMMING the Viking board!!!
0 · Reply
PemvidutideTrader7B
PemvidutideTrader7B Nov. 11 at 8:51 PM
$ALT $VKTX $ETNB $AKRO $MDGL Let’s not forget weight loss!
0 · Reply
PemvidutideTrader7B
PemvidutideTrader7B Nov. 11 at 8:36 PM
$ALT $VKTX $ETNB $AKRO $MDGL Huge start out of the gates for Altimmune.
0 · Reply
Tdorsey1776
Tdorsey1776 Nov. 3 at 4:52 PM
$ETNB Acquisition settled....funds deposited and 89Bio CVRs sitting pretty. GLTA
0 · Reply
mrmarvyn
mrmarvyn Oct. 30 at 8:05 PM
$ETNB I guess that's it for ETNB. It's been a fun ride and hope in 5-10 years I receive a few presents. I'm going to remove them from my watch list.
0 · Reply
Gantz7
Gantz7 Oct. 30 at 3:38 PM
$ETNB And only just need to make 4 Billion in Net sales for one of the CVR products in a single year to get the 6 Dollar. It is staggered in three levels and runs to 2035. So gimme my share money back and I can reinvest it in something again. Today would be nice...
0 · Reply
Tdorsey1776
Tdorsey1776 Oct. 30 at 2:22 PM
$ETNB Keep stacking the CVRs!!! Good luck all
0 · Reply
Gantz7
Gantz7 Oct. 30 at 9:05 AM
$ETNB More CVRs to add to the pile...
0 · Reply
Mergerbrief
Mergerbrief Oct. 29 at 12:16 PM
$ETNB / Roche - Tender Offer Expires MergerBrief.com Full Schedule Of Events
0 · Reply
TwongStocks
TwongStocks Oct. 27 at 5:31 PM
$ETNB Equity Corporate Actions Alert # 2025 - 586 Information Regarding the Tender Offer of 89bio, Inc. (ETNB) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-586 The tender offer by $RHHBY to acquire all of the outstanding common stock of 89bio, Inc. (ETNB) is scheduled to expire one minute after 11:59 p.m. ET, on October 29, 2025, unless extended or terminated. The subsequent merger is tentatively scheduled to close prior to the market open on October 30, 2025. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 on October 29, 2025. If the merger closes as planned, the stock will remain halted on the day of closing (October 30th) and will be suspended effective October 31, 2025. Tender offer: ETNB shareholders will receive $14.50 and a non-transferable contingent value right (CVR) for each share held.
0 · Reply
Letsinvest2024
Letsinvest2024 Oct. 19 at 2:34 AM
$TPST $ETNB $RANI It’s time for $TPST 🥳
0 · Reply
biostock
biostock Oct. 10 at 5:28 AM
AI summary of $SGMT 's FASN Inhibitor VS $AKRO $ETNB 's FGF21 Analogs in MASH. $QQQ $SPY Under the radar, under valued stock.
1 · Reply
biostock
biostock Oct. 9 at 10:40 PM
$SGMT Stocks needs to 10X from here to reach at half of recent valuation paid for $ETNB and $AKRO buyout. $QQQ $SPY Let that sink in.
0 · Reply
IPOARMY1
IPOARMY1 Oct. 9 at 8:10 PM
$ALGS they're buying up the MASH drugs $NVO $AKRO $ETNB
0 · Reply
Tdorsey1776
Tdorsey1776 Oct. 9 at 7:08 PM
$ETNB Tender offer accepted, shares are gone and CVR placeholder is in my account. GLTA
0 · Reply
biostock
biostock Oct. 9 at 2:08 PM
$SGMT Send it to 100 after $ETNB and $AKRO buyout. $SPY $QQQ
0 · Reply
biostock
biostock Oct. 8 at 1:13 AM
$SGMT Massive disconnect in market cap from Billions in TAM in ACNE and MASH. Roche paid billions for $ETNB MASH assets $XBI $QQQ $SPY
0 · Reply
Power2k
Power2k Oct. 6 at 8:35 PM
$VKTX We are worth more than $MTSR and $ETNB combined, period. $PFE $RHHBY
1 · Reply
dogDazeSummer
dogDazeSummer Oct. 6 at 5:07 PM
RA Capital absolutely crushing it with $ASND 10,107,104 or 16% of outstanding shares whereby it represents 29.9% of portfolio and making ATH today at $213 up another 4% today. RA’s 20,013,733 shares of $ETNB bought out last month And 4 of their portfolio companies ironically got sold to $ABBV during last 12 months And of course the newest position $IFRX
0 · Reply
GPTInsights
GPTInsights Oct. 6 at 3:11 PM
$VKTX Viking MC should at least be more in line with the combination of both Metsera and 89bio purchases (~$10.5 billion) which would be over 200% from todays price. This is not even taking into account having the BIC obesity pipeline which should fetch an even higher premium. - $PFE - $MTSR deal equates to over $7 billion. - Viking MC as of today ~3 billion - Viking pipeline further along in regulatory (SC PH3, PO end of PH2, VK2809 completed PH2) - Viking assets demonstrate BIC efficacy and tolerability (SC proved this and PO showed it in PH1/should solidify evidence with PH3 after aggressive PH2 experimental study) - Viking has more cash than MTSR and 89bio - MTSR MASH asset in preclinical/discovery. - 89bio $ETNB MASH/liver assets purchased in deal worth up to $3.5 billion - VK2809 considered to be more effective than 89bio assets
1 · Reply